Every 8-K that ROCKET PHARMACEUTICALS INC (RCKTW) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow RCKTW and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full RCKTW filings page.
Rocket Pharmaceuticals, Inc. (RCKT) adopted a new Severance and Change in Control Program covering U.S. employees not already under separate severance arrangements. Eligibility for non-change-in-control severance requires at least one year of service, and benefits are conditioned on signing a release of claims. The program replaces prior severance arrangements but allows individually approved exceptions.
Rocket also entered into updated executive employment arrangements. CEO Gaurav Shah’s agreement provides a base salary of $674,856, a target bonus of 60% of base salary, and cash and COBRA severance enhancements if terminated without Cause or for Good Reason, with larger amounts upon a qualifying Change in Control termination. General Counsel and Chief Corporate Officer Martin Wilson’s agreement provides a base salary of $547,313, a 45% target bonus, and similar severance and COBRA protections, including enhanced change-in-control terms. An amendment for COO Christopher Stevens aligns his severance and change-in-control protections with this framework while leaving the rest of his prior agreement in effect.
Rocket Pharmaceuticals, Inc. reported a sharp improvement in results for the quarter ended June 30, 2026, driven by U.S. FDA approval of KRESLADI™ and monetization of the associated Priority Review Voucher. Second-quarter net income was $123.2 million, compared with a net loss of $68.9 million a year earlier, helped by a $178.2 million gain from the sale of the voucher. Operating expenses declined to $46.9 million from $71.1 million, reflecting lower research and development and general and administrative costs following a prior restructuring.
For the first six months of 2026, Rocket reported net income of $75.6 million versus a net loss of $130.3 million in the prior-year period. Cash, cash equivalents and investments increased to $283.7 million as of June 30, 2026, from $188.9 million at year-end 2025, and the company expects its cash runway to extend into the second quarter of 2028. Rocket highlighted completion of safety observation for the first three Danon disease patients in its modified pivotal Phase 2 trial, continued FDA interactions on the path to rapidly completing this trial, and multiple planned second-half 2026 milestones across its cardiovascular gene therapy programs, including PKP2-ACM and BAG3-DCM, alongside commercial preparations for KRESLADI.
Rocket Pharmaceuticals reported a positive clinical safety update from the initial three patients treated with RP-A501 under the modified protocol in its global, pivotal Phase 2 trial for Danon disease. The patients received a recalibrated dose of 3.8 × 10¹³ GC/kg plus an immunomodulatory regimen of rituximab, sirolimus, and corticosteroids, given sequentially with at least four weeks between infusions. To date, no thrombotic microangiopathy, capillary leak syndrome, or other significant safety concerns have been observed in these patients.
The pivotal Phase 2 study is designed as a 12-patient, single-arm trial. Rocket is actively engaging with the FDA to align on the path to dosing additional patients and completing the trial and expects an update on the regulatory pathway, as well as a comprehensive Danon disease program update, in the second half of 2026. RP-A501 is a single intravenous AAV9.LAMP2B gene therapy that has demonstrated safety and efficacy in clinical studies and holds multiple U.S. and EU regulatory designations, including RMAT, Fast Track, Rare Pediatric Disease, Orphan Drug, ATMP, and PRIME.
Rocket Pharmaceuticals, Inc. announced leadership changes in its finance organization. John Militello, VP of Finance, Senior Controller, Treasurer and Principal Accounting Officer, has resigned effective July 7, 2026 to pursue other opportunities. Joseph Manhede, currently Associate Vice President, Corporate Controller, will become Principal Accounting Officer effective July 8, 2026.
Manhede, age 48, joined Rocket in April 2026 and previously held senior finance roles at Outlook Therapeutics, Amneal Pharmaceuticals, Unilife Corporation and Celator Pharmaceuticals after starting his career at Deloitte. He is a CPA with an MBA from Holy Family University. The company states there are no new compensatory arrangements or related-party transactions tied to his designation.
Rocket Pharmaceuticals has completed the sale of its Rare Pediatric Disease Priority Review Voucher to a large pharmaceutical company for $180 million in gross, non-dilutive proceeds. The voucher was granted following FDA approval of KRESLADI, Rocket’s gene therapy for severe leukocyte adhesion deficiency-I.
Rocket previously reported cash, cash equivalents and investments of $144.4 million as of March 31, 2026. Pro forma for the voucher sale, this increases to about $322.6 million, which the company expects will fund operations into the second quarter of 2028.
Rocket Pharmaceuticals, Inc. held its 2026 Annual Meeting of Stockholders, where holders of 80,774,659 common shares, representing approximately 74.02% of eligible shares, were present in person or by proxy. Stockholders elected seven directors, with support generally above 59 million votes for each nominee.
They ratified EisnerAmper LLP as independent registered accounting firm for the fiscal year ending December 31, 2026, with 79,195,009 votes for and 1,002,656 against. Stockholders also approved, on a non-binding advisory basis, the compensation of the named executive officers and approved a stock option exchange program as described in the 2026 Proxy Statement.
Rocket Pharmaceuticals, Inc. reported first quarter 2026 results and highlighted major pipeline and financing milestones. The company received FDA accelerated approval for KRESLADI for severe LAD-I and monetized a Rare Pediatric Disease Priority Review Voucher for $180 million.
Pro forma cash, cash equivalents and investments were approximately $322.6 million, providing an expected operational runway into the second quarter of 2028. For the three months ended March 31, 2026, Rocket recorded a net loss of $47.6 million compared with $61.3 million a year earlier, with total operating expenses declining to $48.5 million from $64.4 million. Cash, cash equivalents and investments were $144.4 million as of March 31, 2026.
Rocket Pharmaceuticals, Inc. has entered into a definitive asset purchase agreement to sell its Rare Pediatric Disease Priority Review Voucher for $180 million in cash, payable at closing. The voucher was granted after FDA accelerated approval of KRESLADI, Rocket’s gene therapy for severe LAD-I.
Rocket states that monetizing the voucher provides meaningful non-dilutive capital and extends its cash runway into the second quarter of 2028. The company plans to use the proceeds to support its prioritized cardiovascular gene therapy pipeline, including clinical programs in Danon disease, PKP2-associated arrhythmogenic cardiomyopathy and BAG3-associated dilated cardiomyopathy.
Rocket Pharmaceuticals reported fourth-quarter 2025 net loss of $42,538, improving from $60,327 a year earlier. Full-year 2025 net loss was $223,123, compared with $258,746 in 2024, with net loss per share of $2.01 versus $2.73.
Total operating expenses for 2025 were $231,747, down from $273,205 in 2024, reflecting lower research and development and general and administrative spending and recorded restructuring charges of $3,231. Cash, cash equivalents and investments were $188,929 at December 31, 2025, versus $372,336 a year earlier, which the company says supports an operational runway into the second quarter of 2027.
Operationally, Rocket highlighted progress across its cardiovascular gene therapy programs. The pivotal Phase 2 trial of RP‑A501 for Danon disease is expected to resume in the first half of 2026, the KRESLADI™ BLA for severe LAD‑I has a March 28, 2026 PDUFA date, and first dosing in a Phase 1 study of RP‑A701 for BAG3‑related dilated cardiomyopathy is anticipated in mid‑2026.